REG - Scancell Hlds - Update from iSCIB1+ Clinical Advisory Meeting

Scancell HoldingsAnnouncement

24/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240724:nRSX5353Xa&default-theme=true

RNS Number : 5353X  Scancell Holdings Plc  24 July 2024

24 July 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Scancell Provides Update from iSCIB1+ Clinical Advisory Meeting to Strengthen
Plans for Phase 2/3 Registration Clinical Trial

 

A panel of international key opinion leaders in the treatment of Melanoma
convened in Chicago to offer strategic guidance in the design of Scancell's
Phase 2/3 seamless adaptive registration study.

 

The SCIB1 stage 1 clinical data poster was very well received at ASCO.

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, today announces that a group of leading medical
oncologists in the field of melanoma treatment reviewed and strengthened
Scancell's plan for a Phase 2/3 registration study following completion of the
ongoing SCOPE study.

 

Scancell's plans to conduct an adaptive randomised controlled Phase 2/3
SCOPE-2 trial is supported by a panel of experts. The study is expected to
have an early interim analysis of Overall Response Rate (ORR) based on a
blinded independent centralised review of CT/MRI scans before advancing to the
Phase 3 component where the primary endpoint of progression-free survival will
be analysed at a predetermined landmark.

 

The panel comprised the following members:

 

 Name                 Institution
 Paul Chapman         Weill Cornell Medicine and NewYork-Presbyterian, New York, NY, USA
 Pippa Corrie         Cambridge Cancer Centre, Addenbrooke's Hospital, Cambridge, UK
 Alexander Eggermont  Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
 Georgina Long        Melanoma Institute Australia, Sydney, Australia.
 Sapna Patel          University of Colorado Cancer Center, USA
 Michael Postow       Memorial Sloan Kettering Cancer Center, New York, NY, USA
 Heather Shaw         University College Hospital, London, UK
 Jeffrey Weber        Pelmutter Cancer Center, New York, NY, USA
 Jedd Wolchok         Weill Cornell Medicine and NewYork-Presbyterian, New York, NY, USA

 

A poster, presenting the first stage of the SCOPE study, was also very well
received at ASCO with Prof Durrant, Dr Heather Shaw, Dr Robert Miller and Mr
Fayaz Master discussing the results for three hours with oncologists,
pharmaceutical companies and commercial enterprises.

 

Scancell continues to recruit to the SCOPE study, which includes patients
treated with SCIB1 as well as iSCIB1+.  32/43 patients have been recruited
into the SCIB1 cohort and 22/43 into the iSCIB1+ cohort, with clinical results
expected in Q4 2024 and Q1 2025, respectively.

 

Prof Lindy Durrant, Chief Executive Officer, Scancell said: "We are very
grateful to the esteemed panel for their interest in our SCOPE results and
their input into our further clinical study. The panel felt that the data was
compelling enough to proceed to the Phase 2/3 randomised registration study
upon the completion of the SCOPE study. We were also overwhelmed by the
interest in the poster, which is the most significant response I have seen in
my career."

 

Dr. Wolchok serves as an uncompensated consultant for Scancell Limited.

Dr. Chapman serves as a compensated consultant for Scancell Limited.

 

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Dr Jean-Michel Cosséry, Non-Executive Chairman
 Professor Lindy Durrant, CEO

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)
                                                                          +44 (0) 20 3705 9330

 WG Partners LLP (Joint Broker)

 David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby

 ICR Consilium                                                            +44 (0) 20 3709 5700
 Mary-Jane Elliott/Angela Gray/Lindsey Neville                            scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

About Scancell

 

Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies.

 

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both
of which can recognise damaged or infected cells. In order to destroy such
cancerous or infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs.
The Company's unique approach is that its innovative products target
modifications of proteins and lipids. For the vaccines (Moditope® and
ImmunoBody®) this includes citrullination and homocitrullination of proteins,
whereas its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and
their ability to directly kill tumour cells (AvidiMab®).

 

For further information about Scancell, please visit:
https://www.scancell.co.uk/ (https://www.scancell.co.uk/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEAKXDADFLEFA